SCHEMBL5539360

SCHEMBL5539360

O=C(O)c1ccc(C(=O)c2cccnc2Cl)[nH]1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.62
LMNA P02545 1/20 0.62
POLB P06746 1/20 0.44
KDM4E B2RXH2 2/20 0.43
TDP1 Q9NUW8 1/20 0.43
EGFR P00533 4/20 0.43
CYP1A2 P05177 1/20 0.43
CYP2C9 P11712 1/20 0.43
CYP2C19 P33261 1/20 0.43
L3MBTL1 Q9Y468 2/20 0.42
ALDH1A1 P00352 1/20 0.42
CYP3A4 P08684 1/20 0.42
MAPT P10636 1/20 0.42
ALOX15 P16050 1/20 0.42
TSHR P16473 1/20 0.42
BLM P54132 1/20 0.42
AGER Q15109 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42
NAPRT Q6XQN6 2/20 0.41
NPC1 O15118 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5531213 0.82 SMN1; SMN2 (0.47) SMN1; SMN2LMNAKDM4ETDP1EGFR
SCHEMBL5537699 0.79 POLB (0.47) SMN1; SMN2LMNAPOLBTDP1CYP1A2
SCHEMBL950218 0.79 LMNA (0.73) SMN1; SMN2LMNAPOLBKDM4ETDP1
SCHEMBL353141 0.77 SMN1; SMN2 (1.00) SMN1; SMN2LMNAPOLBKDM4ETDP1
SCHEMBL29412848 0.77 SMN1; SMN2 (1.00) SMN1; SMN2LMNAPOLBKDM4ETDP1
SCHEMBL30792459 0.77 SMN1; SMN2 (1.00) SMN1; SMN2LMNAPOLBKDM4ETDP1
SCHEMBL5534265 0.76 SMN1; SMN2 (0.54) SMN1; SMN2LMNAPOLBKDM4EEGFR
SCHEMBL29565508 0.76 SMN1; SMN2 (0.54) SMN1; SMN2LMNAPOLBKDM4EEGFR
SCHEMBL31572603 0.76 SMN1; SMN2 (0.96) SMN1; SMN2LMNAPOLBKDM4ETDP1
SCHEMBL5250407 0.76 SMN1; SMN2 (0.96) SMN1; SMN2LMNAPOLBKDM4ETDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7186716-B2 3-Pyrrol-pyridopyrazoles and 3-pyrrolyl-indazoles as novel kinase inhibitors SUGEN, INC. (US) 2007-03-06 US disclosed
EP-1545515-A1 3-PYRROLYL-PYRIDOPYRAZOLES AND 3-PYRROLYL-INDAZOLES AS NOVEL KINASE INHIBITORS Sugen, Inc. (US) 2005-06-29 EP disclosed
US-20040092546-A1 3-Pyrrol-pyridopyrazoles and 3-pyrrolyl-indazoles as novel kinase inhibitors SUGEN, INC. 2004-05-13 US disclosed
WO-2004014368-A1 3-PYRROLYL-PYRIDOPYRAZOLES AND 3-PYRROLYL-INDAZOLES AS NOVEL KINASE INHIBITORS SUGEN, INC. (US) 2004-02-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040092546-A1 3-Pyrrol-pyridopyrazoles and 3-pyrrolyl-indazoles as novel kinase inhibitors MAP3K19, MAP3K1, MAP3K7 SMN1; SMN2 3900/4885LMNA 3281/4885POLB 1688/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.